The study will evaluate the efficacy and safety of obinutuzumab in patients with advanced non-pretreated follicular lymphoma (LF) undergoing treatment with obinutuzumab as part of routine clinical practice, measured by the percentage of patients who relapsed in 24 months following the start of treatment (POD24).
Urban ePRO
